Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

Floridaorange Mar. 22 at 12:35 AM

$RXRX NVDA dropped 50% before going parabolic -TSLA dropped 70% before 10x Big returns = pain tolerance

0 · Reply

theRockSeys Mar. 21 at 6:46 PM

$RXRX next round of data coming out soon. Time to put up or shut up. They don’t go to these conferences for nothing.

0 · Reply

HubAllianceModern Mar. 21 at 6:27 PM

$RXRX AI/biotech, just observing calmly.

0 · Reply

MakingMoney20 Mar. 21 at 5:10 PM

$RXRX Brute Science Boys. This is not a Gamble. There's always a New way to do things! Trust the Tech! Recursion! RXRX $$

0 · Reply

Brodman Mar. 21 at 3:46 PM

$RXRX $2's next week....free fall for this over hyped company. Why all the insider selling.....they know where it's headed!!!

0 · Reply

MakingMoney20 Mar. 20 at 7:56 PM

$RXRX Pick up a Great Deal! It's right here. Recursion. RXRX $$

0 · Reply

cntrade1 Mar. 20 at 7:51 PM

$RXRX

0 · Reply

Lh2838 Mar. 20 at 7:17 PM

$RXRX I’ll take some

0 · Reply

Bazzzigar Mar. 20 at 7:06 PM

$RXRX HIMS

0 · Reply

Zio_Fauss Mar. 20 at 6:59 PM

$RXRX

0 · Reply

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Mar 6, 2026, 12:35 PM EST - 15 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 25, 2026, 12:47 PM EST - 24 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 6:30 AM EST - 24 days ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 26 days ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Feb 23, 2026, 7:55 AM EST - 26 days ago

Recursion to Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:30 AM EST - 4 weeks ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 4 weeks ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Jan 22, 2026, 2:54 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Jan 13, 2026, 5:46 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 7:59 AM EST - 2 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 26, 2025, 1:28 PM EST - 3 months ago

3 Small AI Plays to Buy for 2026

ANET INOD

Dec 18, 2025, 11:38 AM EST - 3 months ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:05 AM EST - 3 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 4:37 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 7:32 AM EST - 3 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 3 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 5, 2025, 8:19 AM EST - 3 months ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 1, 2025, 8:30 AM EST - 3 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 21, 2025, 7:43 PM EST - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 10:14 AM EST - 4 months ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 5, 2025, 8:11 PM EST - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 6:30 AM EST - 4 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 4 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 22, 2025, 1:42 PM EDT - 5 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

Oct 8, 2025, 2:51 PM EDT - 5 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Sep 8, 2025, 8:03 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 6:51 PM EDT - 7 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 5, 2025, 2:44 PM EDT - 8 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:30 AM EDT - 8 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 25, 2025, 1:53 PM EDT - 8 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Jul 22, 2025, 7:02 AM EDT - 8 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Jun 10, 2025, 6:14 AM EDT - 10 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 10 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 5, 2025, 1:37 PM EDT - 11 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 6:00 AM EDT - 11 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:02 AM EDT - 11 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 4, 2025, 12:45 PM EDT - 11 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 11 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 22, 2025, 8:34 PM EDT - 11 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 1 year ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Mar 3, 2025, 11:19 AM EST - 1 year ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Feb 28, 2025, 1:16 PM EST - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Floridaorange Mar. 22 at 12:35 AM

$RXRX NVDA dropped 50% before going parabolic -TSLA dropped 70% before 10x Big returns = pain tolerance

0 · Reply

theRockSeys Mar. 21 at 6:46 PM

$RXRX next round of data coming out soon. Time to put up or shut up. They don’t go to these conferences for nothing.

0 · Reply

HubAllianceModern Mar. 21 at 6:27 PM

$RXRX AI/biotech, just observing calmly.

0 · Reply

MakingMoney20 Mar. 21 at 5:10 PM

$RXRX Brute Science Boys. This is not a Gamble. There's always a New way to do things! Trust the Tech! Recursion! RXRX $$

0 · Reply

Brodman Mar. 21 at 3:46 PM

$RXRX $2's next week....free fall for this over hyped company. Why all the insider selling.....they know where it's headed!!!

0 · Reply

MakingMoney20 Mar. 20 at 7:56 PM

$RXRX Pick up a Great Deal! It's right here. Recursion. RXRX $$

0 · Reply

cntrade1 Mar. 20 at 7:51 PM

$RXRX

0 · Reply

Lh2838 Mar. 20 at 7:17 PM

$RXRX I’ll take some

0 · Reply

Bazzzigar Mar. 20 at 7:06 PM

$RXRX HIMS

0 · Reply

Zio_Fauss Mar. 20 at 6:59 PM

$RXRX

0 · Reply

Brodman Mar. 20 at 5:58 PM

$RXRX Also doesn ’t help when the CEO continues to sell/dump shares along with other insiders….RXRX head south for sure $1’s incoming

1 · Reply

Brodman Mar. 20 at 4:58 PM

$RXRX Nvidia saw where this was headed and said we are out!! This over hyped stock just continues to head south. Heading to the $1's....it's a dog, get out now before it gets in the 1's.

0 · Reply

DragonAlgo Mar. 20 at 4:50 PM

🐉 $RXRX PUT — DragonAlgo® Signal Contract: RXRX PUT Expiry: 2026-03-20 | Strike: $4.00 | Type: PUT Option Plan (premium): Entry: $0.61 Stop: $0.44 TP1: $0.80 TP2: $1.05 TP3: $1.48 🔗 https://dragonalgo.com

0 · Reply

cntrade1 Mar. 20 at 4:16 PM

$RXRX easy buy 💎

1 · Reply

MoneyFairyBlessings Mar. 20 at 1:50 PM

$RXRX Going to $4.08.

1 · Reply

Spartangio Mar. 20 at 1:18 PM

$RXRX cmon nobody cares about P1/2 drugs.. Why this matters for RXRX: PI3K pathway = same space Recursion works in 🎯 Novartis paying $2B UPFRONT for Phase 1/2 drug = validates early stage AI-discovered drugs have massive value Rich Law — credible biotech analyst — explicitly tagged RXRX as relevant

0 · Reply

Toto10 Mar. 20 at 9:38 AM

$RXRX Buy N O W you filthy animals!

0 · Reply

shooshmonk Mar. 20 at 8:43 AM

$RXRX was thinking about thinking to start a position but then saw Nvidia sold their shares

1 · Reply

Tobitski Mar. 20 at 7:49 AM

$RXRX Since upcoming presentation from rxrx and Astrazenica which is a BIG pharma we could expect collaboration coming…. Starting to get really interesting… not hype just saying pay attention. ….💣 ….🚀

0 · Reply

DragonAlgo Mar. 19 at 11:32 PM

🐉 $RXRX CALL — DragonAlgo® Signal Contract: RXRX CALL Expiry: 2026-03-20 | Strike: $2.00 | Type: CALL Option Plan (premium): Entry: $1.39 Stop: $1.00 TP1: $1.80 TP2: $2.35 TP3: $3.32 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

MakingMoney20 Mar. 19 at 11:00 PM

$RXRX Insain to share the side lines at this price! Rare opportunity for cutting edge Tech! Recursion all the way! RXRX $$

0 · Reply

MoneyFairyBlessings Mar. 19 at 9:26 PM

Besides Big Fly $ONDS, ☺️, some little flies for fun and sizzles 💥- $RXRX $EVTV $INTZ … Super Flying Friday coming up!👏😃

0 · Reply

Market Cap	1.75B
Revenue (ttm)	74.68M
Net Income (ttm)	-644.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-863.36%
Debt to Equity Ratio	0.01

Volume	26,878,000
Avg Vol	19,326,260
Day's Range	N/A - N/A
Shares Out	527.40M
Stochastic %K	11%
Beta	0.97
Analysts	Sell
Price Target	$6.71